Premium
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant‐ineligible patients with myeloma who are treated with bortezomib‐based induction
Author(s) -
Boyle Stephen,
Wellard Cameron,
Moore Elizabeth M.,
Blacklock Hilary,
Harrison Simon J.,
Ho Phoebe Joy,
Hocking Jay,
McQuilten Zoe K.,
Quach Hang,
Spearing Ruth,
Wood Erica M.,
Spencer Andrew,
Mollee Peter
Publication year - 2021
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13677
Subject(s) - multiple myeloma , bortezomib , medicine , family medicine
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom